How to Cure Depression: What Medicine and Science Actually Say

There is a reason the most commonly searched questions about depression include the word ‘cure.’ People want to know if this ends. If the months of feeling this way have a finish line.

The honest answer is not what most people expect. Depression is not cured the way a bacterial infection is. The word ‘remission’ is more accurate. But remission is real, sustained, and achievable for most people who get the right treatment and stay with it long enough to let it work.

What This Page Covers

• Why ‘cure’ is the wrong frame and what remission actually means
• First-line treatment options and what the evidence shows
• Antidepressant response rates and what to expect
• Why treatment adherence is the central clinical problem
• Combination therapy and when it’s indicated
• What remission maintenance requires
• How SiggyMD approaches long-term depression care

Why ‘Cure’ Is the Wrong Frame

In medicine, ‘cure’ means permanent elimination of a disease with no recurrence risk. Depression doesn’t work that way for most people. Major depressive disorder is characterized by depressed mood or loss of pleasure, alongside specific symptoms present most of the day for at least two weeks, and it recurs in the majority of patients who have one episode.

The more useful question is: can depression go away? Can it stay away? Can I feel like myself again?

The answer to all three is yes, for most people. The clinical term is remission: no longer meeting the criteria for a depressive episode. Remission can last years or decades. For some patients, a single episode followed by adequate treatment and no recurrence is the whole story.

What Treatment for Depression Actually Does

Treatment doesn’t eliminate the underlying vulnerability to depression. It achieves remission by reducing active symptoms and stabilizing the neurobiological processes driving them. Continuing treatment after remission maintains that stability.

Pharmacotherapy, especially selective serotonin reuptake inhibitors, remains the most frequent option for treating depression during the acute phase. Depression-focused psychotherapy is the second most common option for achieving remission and preventing relapses.

Two things happen in successful treatment: active symptoms reduce enough that you no longer meet the criteria for a depressive episode, and the brain returns to a functional baseline that, with maintenance treatment, holds.

Both steps matter. Treating only the acute episode without maintenance is the most common reason depression recurs.

First-Line Treatment Options

For patients with moderate depression, the 2023 American College of Physicians clinical guidelines recommend either an SSRI or CBT as equivalent first-line options. Combination treatment is recommended for more severe presentations.

Antidepressant Medications (SSRIs and SNRIs)

SSRIs are the first-line pharmacological treatment for depression: sertraline, escitalopram, fluoxetine, and paroxetine are the most commonly prescribed. SNRIs (venlafaxine, duloxetine) are a closely related class with similar first-line evidence.

The response rate following first-line SSRI treatment ranges from 40 to 60 percent, with remission rates on a first SSRI of 30 to 45 percent. This is the starting point, not a ceiling. Most patients who don’t respond to the first medication respond to a subsequent one.

SSRIs require four to six weeks for therapeutic mood benefit to develop. Side effects often peak in weeks one through three, before the mood benefit arrives. This mismatch is the central clinical problem: patients stop during the early window when they feel the costs but not yet the benefit.

Cognitive Behavioral Therapy (CBT)

CBT and interpersonal therapy are the most evidence-based psychotherapies for depression. For mild to moderate depression, CBT is as effective as medication for many patients. It teaches skills to identify and reframe negative thought patterns and break the behavioral cycles that maintain depression.

CBT is not supportive talking. It is structured, skills-based treatment with specific homework between sessions, targeting cognitive and behavioral patterns rather than just processing feelings.

Combination Treatment

The ACP guidelines recommend combination treatment (medication plus CBT) for patients with more severe depression and those who have not had adequate response to monotherapy. Together, they address different maintaining mechanisms and produce better long-term outcomes than either alone.

The Adherence Problem

The biggest obstacle to depression remission is not treatment failure. It is treatment dropout.

Approximately 25 percent of patients stop antidepressants within one month, and 44 percent stop within three months. Most stop during the exact window when the medication hasn’t yet worked but side effects are still present. Stopping at week three is almost always stopping before the medication had a chance to work.

Side effects typically peak and then resolve between weeks one and four. Therapeutic benefit typically arrives after four to six weeks. Patients who stop at week three experience the cost without ever reaching the benefit.

What changes this: monitoring. Someone checking in at week three who can say ‘what you’re experiencing right now is expected, and week six typically looks different’ changes the probability a patient stays with treatment long enough to know whether it works.

Behavioral Activation

One of the most evidence-based components of depression treatment doesn’t require a prescription.

Depression pulls people out of activities that used to bring satisfaction. The withdrawal makes sense when energy is depleted. But behavioral withdrawal is self-reinforcing: removing pleasurable activities removes the behavioral reinforcement that supports mood regulation.

Behavioral activation means re-engaging with activities before you feel like it, not when motivation arrives, but to produce it. The evidence for this approach is strong, and it works independently of medication. Starting small matters more than starting big.

Maintenance: The Step Most People Skip

Achieving remission is the first clinical goal. Sustaining it is the second, and the one most often overlooked.

Research on long-term treatment of major depressive disorder shows that patients who continue medication after achieving remission have substantially lower relapse rates than those who discontinue treatment as soon as symptoms resolve.

The risk of recurrence increases with each depressive episode. This is why prescribers generally recommend continuing treatment for at least 6 to 9 months after a first remission, and longer for patients with a history of multiple episodes.

Stopping medication because you feel better is the most common trigger for relapse. Feeling better is often evidence that treatment is working, not that it is no longer needed.

About SiggyMD

Getting to remission requires more than a prescription. It requires monitoring during the adherence window, real-time adjustment when side effects arise, and clinical guidance through the difficult early weeks.

SiggyMD provides clinically supervised medication management for depression and anxiety. The anonymous intake is free and requires no login, name, or email. A licensed prescriber reviews your full clinical picture before anything is prescribed. Daily check-ins from week one track how medication is affecting sleep, energy, mood, and side effects in the moment when adjustments actually help.

“The patients I see who don’t get better are almost always the ones who stopped at week three or four,” says Elizabeth Lokenauth, PA-C, of the SiggyMD clinical team. “The medication didn’t fail them. The system failed them by not checking in at the hardest moment. That window is exactly when having someone in your corner matters most.”

For more on managing depression, read our guides on how to get out of depression, what depression actually is, and how to deal with depression day to day.

Start your anonymous intake at SiggyMD to connect with a licensed prescriber who will be there with you through the parts that are hardest to do alone.

What Members Are Saying

MA

M.A., 37

Major Depressive Disorder

“I’d tried two antidepressants before, both times stopping around week three because I felt worse. I didn’t know that’s when most people stop, or that week six is supposed to look different. When someone was actually monitoring how I felt at week three and telling me this was expected, I stayed with it for the first time. It worked at week six. I’ve been in remission for fourteen months.”

JB

J.B., 51

Recurrent Depression

“I thought feeling better meant I didn’t need medication anymore. My prescriber explained the relapse data and what maintenance treatment actually does. I’d had three episodes in ten years, all triggered by stopping too soon. I stayed with the treatment this time. I’ve been well for two years.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary.

Sources

1. National Institute of Mental Health. Depression. NIH Publication No. 24-MH-8079. Revised 2024.

2. Qaseem A, et al. Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder. Annals of Internal Medicine. 2023.

3. PMC. Major depressive disorder: Validated treatments and future challenges. World Journal of Clinical Cases. 2021.

4. Agency for Healthcare Research and Quality. Depression Treatment after Unsatisfactory Response to SSRIs. Effective Health Care Program. Accessed June 2026.

5. Dell’Osso B, et al. How to improve adherence to antidepressant treatments in patients with major depression. Annals of General Psychiatry. 2020;19(1):61.

6. Keller MB, et al. Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder. Journal of Clinical Psychiatry. 2007.

7. American Psychiatric Association. What Is Depression? Reviewed April 2024.

8. American Psychological Association. APA Clinical Practice Guideline for the Treatment of Depression. 2019.